尼麦角林联合长春西汀治疗急性脑梗死的临床研究

目的观察采用尼麦角林联合长春西汀治疗急性脑梗死患者的临床效果。方法选取2016年8月—2017年8月池州市第二人民医院收治的脑梗死患者131例,随机分成对照组(65例)和治疗组(66例)。对照组患者静脉滴注长春西汀注射液,30 mg加入生理盐水500 m L,1次/d;治疗组患者在对照组基础上口服尼麦角林片,2片/次,2次/d。两组患者均治疗两周。观察两组患者临床疗效,同时比较治疗前后两组患者NIHSS和BI评分及同型半胱氨酸(Hcy)水平。结果治疗后,对照组和治疗组的总有效率分别为84.62%和96.97%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者NIHSS评分显著降低,BI评分显著升高,同组治疗前后比较差异具有统计学意义(P0.05),且治疗后治疗组NIHSS和BI评分显著优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者Hcy水平显著降低,同组治疗前后比较差异具有统计学意义(P0.05),且治疗后治疗组患者Hcy水平明显低于对照组(P0.05)。结论尼麦角林联合长春西汀治疗急性脑梗死患者疗效明显,安全性高,具有一定的临床推广应用价值。

Clinical study on nicergoline combined with vinpocetine in treatment of acute cerebral infarction

Objective To observe the clinical effect of nicergoline combined with vinpocetine in treatment of acute cerebral infarction. Methods Patients (131 cases) with acute cerebral infarction in Chizhou Second People''s Hospital from August 2016 to August 2017 were randomly divided into control (65 cases) and treatment (66 cases) groups. Patients in the control group were iv administered with Vinpocetine Injection, 30 mg added into normal saline 500 mL, once daily. Patients in the treatment group were po administered with Nicergoline Tablets on the basis of the control group, 2 tablets/time, twice daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the NIHSS and BI scores, the Hcy levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 84.62% and 96.97% respectively, and there were differences between two groups (P < 0.05). After treatment, the NIHSS scores in two groups were significantly decreased (P < 0.05), but BI scores were significantly increased (P < 0.05), and the NIHSS and BI scores in the treatment group after treatment were significantly better than those in the control group (P < 0.05). After treatment, the Hcy level in two groups was significantly decreased, and the difference was statistically significant in the same group (P < 0.05), and the Hcy level in the treatment group after treatment was significantly lower than that in the control group (P < 0.05). Conclusion Nicergoline combined with vinpocetine in treatment of acute cerebral infarction has obvious curative effect with high safety, which has a certain clinical application value.